BeyondSpring reports FY2025 net loss $8.7M; Plinabulin Phase 3 survival benefit confirmed, DUBLIN-4 planned

BeyondSpring Inc.

R&D expense $4.4M, G&A $4.6M; cash $12.6M as of Dec 31, 2025.
Plinabulin+docetaxel achieved OS HR 0.72 in non-squamous NSCLC; DUBLIN-4 confirmatory trial planned.
SEED Therapeutics dosed first patient in Phase 1a for ST-01156; completed $30M Series A-3 financing.
Sold portion of SEED preferred shares for ~$35.4M gross proceeds; first closing $7.35M in Feb 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BeyondSpring Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 25, 2026, BeyondSpring Inc. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BeyondSpring Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-001890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.